(S)-[3-(N,N-Dibenzylamino)-2-hydroxypropoxy]-2-amino-3-nitrobenzene | 189119-13-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-[3-(N,N-Dibenzylamino)-2-hydroxypropoxy]-2-amino-3-nitrobenzene
• 英文别名: (2S)-1-(2-amino-3-nitrophenoxy)-3-(dibenzylamino)propan-2-ol
• CAS: 189119-13-9
• 化学式: C₂₃H₂₅N₃O₄
• 分子量: 407.469
• InChiKey: QKHAGDFRGCDARQ-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-[3-(N,N-Dibenzylamino)-2-hydroxypropoxy]-2-amino-3-nitrobenzene 在 palladium on activated charcoal 盐酸 、 sodium dithionite 、 ammonium formate 、 碳酸氢钠 作用下， 以 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 反应 31.0h， 生成 (S)-4-[2-hydroxy-3-aminopropoxy]-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  Potent benzimidazolone based human β3-adrenergic receptor agonists

  摘要：

  The synthesis and biological evaluation of a series of benzimidazolone beta(3) adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone moiety was observed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.010
• 作为产物：
  描述：

  2-氨基-3-硝基苯酚 在 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 28.0h， 生成 (S)-[3-(N,N-Dibenzylamino)-2-hydroxypropoxy]-2-amino-3-nitrobenzene
  参考文献：
  名称：

  Potent benzimidazolone based human β3-adrenergic receptor agonists

  摘要：

  The synthesis and biological evaluation of a series of benzimidazolone beta(3) adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone moiety was observed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.010

文献信息

• Selective beta3 adrenergic agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0764640A1

  公开（公告）日：1997-03-26

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及对选择性β3肾上腺素能受体激动剂在治疗2型糖尿病和肥胖方面的应用。该发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物施用具有I和II式的化合物。
• Selective .beta.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US05786356A1

  公开（公告）日：1998-07-28

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明属于医学领域，特别是涉及治疗2型糖尿病和肥胖的领域。更具体地说，本发明涉及用于治疗2型糖尿病和肥胖的选择性β3肾上腺素受体激动剂。该发明提供了化合物和治疗2型糖尿病的方法，包括给予需要的哺乳动物化合物I和II的方法：##STR1##
• Selective .beta.-3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US05840738A1

  公开（公告）日：1998-11-24

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及选择性β3肾上腺素受体激动剂，用于治疗2型糖尿病和肥胖。该发明提供了化合物和方法，用于治疗2型糖尿病，包括向需要的哺乳动物给予公式I和II的化合物：##STR1##
• Selective &bgr;3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06265581B1

  公开（公告）日：2001-07-24

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是用于治疗II型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3肾上腺素能受体激动剂，用于治疗II型糖尿病和肥胖症。本发明提供了化合物和治疗II型糖尿病的方法，包括向需要的哺乳动物注射式I和式II的化合物。
• Selective .beta..sub.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06075040A1

  公开（公告）日：2000-06-13

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明涉及医学领域，特别是在治疗II型糖尿病和肥胖症方面。更具体地说，本发明涉及选择性β3肾上腺素受体激动剂，用于治疗II型糖尿病和肥胖症。该发明提供了化合物和治疗II型糖尿病的方法，包括向需要的哺乳动物中给予公式I和II的化合物： ##STR1##